Effects of Common Polymorphisms on the Properties of Recombinant Human Methylenetetrahydrofolate Reductase

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2001 Dec 14

PMID 11742092

Citations 129

Authors

K Yamada

Z Chen

R Rozen

R G Matthews

Affiliations

Soon will be listed here.

Abstract

Methylenetetrahydrofolate reductase (MTHFR) catalyzes the conversion of methylenetetrahydrofolate to methyltetrahydrofolate, the major methyl donor for the conversion of homocysteine to methionine. Two common polymorphisms of the human enzyme have been identified: 677C>T, which leads to the substitution of Ala-222 by valine, and 1298A>C, which leads to the replacement of Glu-429 by alanine; the former polymorphism is the most frequent genetic cause of mild hyperhomocysteinemia, a risk factor for cardiovascular disease. By using a baculovirus expression system, recombinant human MTHFR has been expressed at high levels and purified to homogeneity in quantities suitable for biochemical characterization. The Glu429Ala protein has biochemical properties that are indistinguishable from the wild-type enzyme. The Ala222Val MTHFR, however, has an enhanced propensity to dissociate into monomers and to lose its FAD cofactor on dilution; the resulting loss of activity is slowed in the presence of methyltetrahydrofolate or adenosylmethionine. This biochemical phenotype is in good agreement with predictions made on the basis of studies comparing wild-type Escherichia coli MTHFR with a mutant, Ala177Val, homologous to the Ala222Val mutant human enzyme [Guenther, B. D., et al. (1999) Nat. Struct. Biol. 6, 359-365].

Citing Articles

Evaluating the Association Between Methylenetetrahydrofolate Reductase (Rs1801131 and Rs1801133) Gene Polymorphisms and Severity of Coronary Lesions in Patients With STEMI and NSTEMI: A Retrospective Cross-Sectional Study.

Nazarzadeh B, Ghazanfari S, Karimi F, Moezibady S, Salmani F, Dastjerdi K Health Sci Rep. 2025; 8(1):e70284.

PMID: 39807484 PMC: 11725607. DOI: 10.1002/hsr2.70284.

Nutrigenetic Investigations in Preeclampsia.

Kukor Z Nutrients. 2024; 16(19.

PMID: 39408215 PMC: 11478722. DOI: 10.3390/nu16193248.

Chlorquinaldol Alleviates Lung Fibrosis in Mice by Inhibiting Fibroblast Activation through Targeting Methionine Synthase Reductase.

Yang X, Lin G, Chen Y, Lei X, Ou Y, Yan Y ACS Cent Sci. 2024; 10(9):1789-1802.

PMID: 39345816 PMC: 11428390. DOI: 10.1021/acscentsci.4c00798.

Unveiling the Therapeutic Potential of Folate-Dependent One-Carbon Metabolism in Cancer and Neurodegeneration.

Sobral A, Cunha A, Silva V, Gil-Martins E, Silva R, Barbosa D Int J Mol Sci. 2024; 25(17).

PMID: 39273288 PMC: 11395277. DOI: 10.3390/ijms25179339.

Revitalising Riboflavin: Unveiling Its Timeless Significance in Human Physiology and Health.

Aragao M, Pires L, Santos-Buelga C, Barros L, Calhelha R Foods. 2024; 13(14).

PMID: 39063339 PMC: 11276209. DOI: 10.3390/foods13142255.

References

She Q, NAGAO I, Hayakawa T, Tsuge H . A simple HPLC method for the determination of S-adenosylmethionine and S-adenosylhomocysteine in rat tissues: the effect of vitamin B6 deficiency on these concentrations in rat liver. Biochem Biophys Res Commun. 1994; 205(3):1748-54. DOI: 10.1006/bbrc.1994.2871. View

Jacques P, Bostom A, Williams R, Ellison R, Eckfeldt J, Rosenberg I . Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996; 93(1):7-9. DOI: 10.1161/01.cir.93.1.7. View

Boushey C, Beresford S, Omenn G, Motulsky A . A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995; 274(13):1049-57. DOI: 10.1001/jama.1995.03530130055028. View

Kozak M . Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res. 1984; 12(2):857-72. PMC: 318541. DOI: 10.1093/nar/12.2.857. View

Bates C, Fuller N . The effect of riboflavin deficiency on methylenetetrahydrofolate reductase (NADPH) (EC 1.5.1.20) and folate metabolism in the rat. Br J Nutr. 1986; 55(2):455-64. DOI: 10.1079/bjn19860051. View

Kang S, Passen E, Ruggie N, Wong P, Sora H . Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1993; 88(4 Pt 1):1463-9. DOI: 10.1161/01.cir.88.4.1463. View

Chen Z, Karaplis A, Ackerman S, Pogribny I, Melnyk S, Chen M . Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet. 2001; 10(5):433-43. DOI: 10.1093/hmg/10.5.433. View

Blount B, Mack M, Wehr C, MacGregor J, Hiatt R, Wang G . Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci U S A. 1997; 94(7):3290-5. PMC: 20362. DOI: 10.1073/pnas.94.7.3290. View

Rosenblatt D, Erbe R . Methylenetetrahydrofolate reductase in cultured human cells. II. Genetic and biochemical studies of methylenetetrahydrofolate reductase deficiency. Pediatr Res. 1977; 11(11):1141-3. DOI: 10.1203/00006450-197711000-00005. View

10.

van der Put N, Gabreels F, STEVENS E, Smeitink J, Trijbels F, Eskes T . A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am J Hum Genet. 1998; 62(5):1044-51. PMC: 1377082. DOI: 10.1086/301825. View

11.

Daubner S, Matthews R . Purification and properties of methylenetetrahydrofolate reductase from pig liver. J Biol Chem. 1982; 257(1):140-5. View

12.

Matthews R . Methylenetetrahydrofolate reductase from pig liver. Methods Enzymol. 1986; 122:372-81. DOI: 10.1016/0076-6879(86)22196-5. View

13.

Guenther B, Sheppard C, Tran P, Rozen R, Matthews R, Ludwig M . The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat Struct Biol. 1999; 6(4):359-65. DOI: 10.1038/7594. View

14.

Refsum H, Ueland P, Nygard O, Vollset S . Homocysteine and cardiovascular disease. Annu Rev Med. 1998; 49:31-62. DOI: 10.1146/annurev.med.49.1.31. View

15.

Graham I, Daly L, Refsum H, Robinson K, Brattstrom L, Ueland P . Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997; 277(22):1775-81. DOI: 10.1001/jama.1997.03540460039030. View

16.

Shields D, Kirke P, Mills J, Ramsbottom D, Molloy A, Burke H . The "thermolabile" variant of methylenetetrahydrofolate reductase and neural tube defects: An evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. Am J Hum Genet. 1999; 64(4):1045-55. PMC: 1377828. DOI: 10.1086/302310. View

17.

Hustad S, Ueland P, Vollset S, Zhang Y, Schneede J . Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem. 2000; 46(8 Pt 1):1065-71. View

18.

Frosst P, Blom H, Milos R, Goyette P, Sheppard C, Matthews R . A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995; 10(1):111-3. DOI: 10.1038/ng0595-111. View

19.

Matthews R, Haywood B . Inhibition of pig liver methylenetetrahydrofolate reductase by dihydrofolate: some mechanistic and regulatory implications. Biochemistry. 1979; 18(22):4845-51. DOI: 10.1021/bi00589a012. View

20.

Ueland P, Hustad S, Schneede J, Refsum H, Vollset S . Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci. 2001; 22(4):195-201. DOI: 10.1016/s0165-6147(00)01675-8. View